Zymeworks has dosed the first patient in a Phase 1 clinical trial evaluating ZW191, an antibody-drug conjugate, for advanced solid tumors expressing folate receptor-α (FRα).
Zymeworks has dosed the first patient in a Phase 1 clinical trial evaluating ZW191, an antibody-drug conjugate, for advanced folate receptor-α (FRα)-expressing solid tumors.